Literature DB >> 19714619

Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model.

Shangxi Liu1, Mohit Kapoor, Christopher P Denton, David J Abraham, Andrew Leask.   

Abstract

OBJECTIVE: Activated adhesive signaling is a hallmark of fibroblasts isolated from the scars of scleroderma (systemic sclerosis) lesions. Beta-1 integrin plays a key role in adhesive signaling. The aim of the present study was to examine the role of beta1 integrin in a mouse model of skin scleroderma using mice bearing a fibroblast-specific deletion of beta1 integrin.
METHODS: Cutaneous sclerosis was induced by subcutaneous injection of bleomycin. Control groups were treated with phosphate buffered saline. Mice bearing a fibroblast-specific deletion of beta1 integrin and control mice were investigated. Dermal thickness, collagen production, and the number of alpha-smooth muscle actin-positive cells were determined. The quantity of the collagen-specific amino acid hydroxyproline was also measured.
RESULTS: Bleomycin treatment induced marked cutaneous thickening and fibrosis in control mice. Conversely, the deletion of beta1 integrin resulted in resistance to bleomycin-induced fibrosis.
CONCLUSION: Expression of beta1 integrin by fibroblasts is required for fibrogenesis. Inhibition of beta1 integrin may be a viable method to alleviate the development of cutaneous sclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19714619     DOI: 10.1002/art.24801

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  40 in total

Review 1.  Clinical, cellular, and molecular aspects in the pathophysiology of rosacea.

Authors:  Martin Steinhoff; Jörg Buddenkotte; Jerome Aubert; Mathias Sulk; Pawel Novak; Verena D Schwab; Christian Mess; Ferda Cevikbas; Michel Rivier; Isabelle Carlavan; Sophie Déret; Carine Rosignoli; Dieter Metze; Thomas A Luger; Johannes J Voegel
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

Review 2.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

3.  Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.

Authors:  Sen Shi; Swayam Prakash Srivastava; Megumi Kanasaki; Jianhua He; Munehiro Kitada; Takako Nagai; Kyoko Nitta; Susumu Takagi; Keizo Kanasaki; Daisuke Koya
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

4.  Activation of latent TGFβ by αvβ 1 integrin: of potential importance in myofibroblast activation in fibrosis.

Authors:  Andrew Leask; James Hutchenreuther
Journal:  J Cell Commun Signal       Date:  2014-01-24       Impact factor: 5.782

5.  CCN2: a bona fide target for anti-fibrotic drug intervention.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-03-06       Impact factor: 5.782

6.  The fibroblast integrin alpha11beta1 is induced in a mechanosensitive manner involving activin A and regulates myofibroblast differentiation.

Authors:  Sergio Carracedo; Ning Lu; Svetlana N Popova; Roland Jonsson; Beate Eckes; Donald Gullberg
Journal:  J Biol Chem       Date:  2010-02-02       Impact factor: 5.157

7.  Possible strategies for anti-fibrotic drug intervention in scleroderma.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-01-29       Impact factor: 5.782

Review 8.  Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancers.

Authors:  Andrew Leask
Journal:  Am J Physiol Cell Physiol       Date:  2020-03-04       Impact factor: 4.249

Review 9.  Integrin-mediated regulation of TGFβ in fibrosis.

Authors:  Neil C Henderson; Dean Sheppard
Journal:  Biochim Biophys Acta       Date:  2012-10-06

10.  Connective tissue growth factor is induced in bleomycin-induced skin scleroderma.

Authors:  Shangxi Liu; Reza Taghavi; Andrew Leask
Journal:  J Cell Commun Signal       Date:  2009-11-15       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.